Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Hi, everyone. My name is Maurice Raycroft and I'm one of the biotech analysts at Jefferies. I would like to introduce Yvonne Greenstreet, the CEO of Alnylam. Great to see you, Yvonne, and thanks so much for joining us today.
Thanks, Maurice. And a pleasure to be here and to be in person again across the live audience. It's a lot more fun doing it with you today. So I'm just going to make a few introductory remarks if that's the case but I just want to remind people that Alnylam is the leading RNAi company. We're incredibly proud of our progress. We now have 4 marketed medicines, 3 that we are commercializing ourselves ONPATTRO, GIVLAARI and OXLUMO and Leqvio which has been commercialized by Novartis. We have a very rich clinical pipeline, which continues to deliver exciting progress. And you may have seen today that we are sharing the results from a Phase II study with Cemdisiran in patients with IgA nephropathy.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
